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Abstract
In the present study, the effects of subchronic treatments (4 weeks) of hypercholesterolemic
(single) and diabetic-hypercholesterolemic (combined) rats with 4 (3H) quinazolinone and 2
halogenated derivatives (6, 8-dibromo-2-methy-4 (3H) quinazolinone and 6-iodo-2-methyl-4(3H)
quinazolinone) at a sublethal dose level (2 mg/Kg) on cholesterol metabolism were investigated.
Bezafibrate, a hypolipidemic drug was used as a reference compound for data comparison.
Treatment of rats with single and combined hypercholesterolemia with quinazolinone compounds
gave rise to highly significant reductions in serum total cholesterol and cholesterol ester levels,
whereas serum triacylglycerol level was significantly reduced only after treatment with halogen-
substituted quinazolinones in single hyper-cholesterolemia, compared to the control group. The
effects of different quinazolinones and bezafibrate on reduction of serum LDL-C level were
comparable in single hypercholesterolemia but significantly different in combined
hypercholesterolemia. Results obtained from this study suggest that the antihyperlipidemic effect
of quinazolinone compounds was brought about by inhibition of dietary cholesterol absorption and
/ or intestinal ACAT activity.
Introduction
Cardiovascular diseases remain by far the number one
cause of death for both men and women of all ethnic
backgrounds. Although many causative factors of these
diseases are recognized (smoking, high blood pressure,
genetic background, diabetes mellitus and obesity) high
serum LDL-C and elevated total cholesterol levels are the
most prevalent indicators for susceptibility to atheroscle-
rotic heart disease [1,2]. Atherosclerosis is a disorder of
the arterial wall characterized by accumulation of choles-
terol ester in cells derived from the monocyte-macrophage
line, smooth muscle cell proliferation and fibrosis, and
results in narrowing the blood vessel [3]. An association
of dietary cholesterol with cardiac and cerebral vascular
diseases is based on several lines of evidence, including
studies in animal models and epidemiological data in
humans [4].
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Dyslipidemia, hallmarked by low plasma HDL-C and
high LDL-C and triacylglycerol levels, is common in
patients with diabetes mellitus. These lipoprotein abnor-
malities are held to be responsible for considerable cardi-
ovascular disease-related morbidity and mortality [5]. The
risk for cardiovascular disease is increased approximately
2 to 4 fold in patients with diabetes mellitus compared
with non-diabetic controls [6].
There are many classes of lipid lowering agents available,
these drugs have different mechanisms of action and var-
iable efficacy depending on the lipid profile of an individ-
ual. In spite of their lipid-lowering effect, these drugs have
many side effects. Thus, research is still pursuing to find
out novel agents that are more effective and safe. The
4(3H)-quinazolinone derivatives (a derivative of the par-
ent compound quinazoline) have been shown as a group
of compounds of broad medical interest. Quinazolinones
are reported to exhibit antibacterial [7], antiviral [8], anti-
cancer [9], antihypertensive [10] and anti-inflammatory
activities [11]. The antihyperlipidemic and antihypercho-
lesterolemic activities of quinazolinone derivatives are
reported and the activities of the tested compounds were
almost equal to that of β-sitosterol (a plant sterol of
hypolipidemic activity) [1,12].
The present work aims at investigating the antihyperlipi-
demic activities of 4 (3H) quinazolinone and two halo-
genated derivatives (6, 8-dibromo- and 6-iodo-2-methyl-
4(3H) quinazolinone) in hypercholesterolemic and/or
diabetic rats. Bezafibrate was adopted in this study as a ref-
erence hypolipidemic drug for data comparison.
Materials and methods
Chemicals
4(3H)-quinazolinone was synthesized by stirring a mix-
ture of formamide and anthranilic acid at 120–125°C for
4 h. [7]. The two halogenated derivatives; 6, 8-dibromo-2-
methyl-4(3H)-quinazolinone and 6-iodo-2-methyl-
4(3H)-quinazolinone were synthesized as previously
described [13]. The crude compounds were filtered,
washed several times with hot water then recrystallized
from ethanol. The structures of the synthesized com-
pounds were verified by IR and mass spectral analyses.
Animals
A total of 130 adult male Swiss albino rats weighing 150–
180 g were used throughout this study. The animals were
housed in steel mesh cages (4/cage) and maintained for a
week-acclimatization period on a commercial pellet diet,
which was finely ground before being administered to
animals.
Preparation and Administration of Chemical Compounds
One tablet (200 mg) of the bezafibrate (trivial name: Bez-
alip, GlaxoWellcome, UK) was finely ground and dis-
solved in 50 ml of distilled water to prepare a stock
solution of 4 mg/ml. The solution was prepared weekly
and stored in a well stoppered bottle at 4°C. Bezafibrate
was daily administered to rats by a stainless-steel gavage
needle at a dose level of 18 mg/kg body weight, which is
equivalent to the human dose calculated from the conver-
sion table of Paget and Barnes [14].
A weight of 50 mg quinazolinone and its halogenated
derivatives was dissolved in 50 ml of 10% (v/v) polyeth-
ylene glycol to prepare stock solutions (1 mg/ml). The
solutions were prepared weekly and stored in a well-stop-
pered bottle at 4°C. The quinazolinone compounds were
orally administered to animals at a sublethal dose level of
2 mg/kg body weight. The LD50 value of quinazolinone
was previously reported to be 320 mg/kg body weight on
i.p. administration in rats [15]. The toxicities of dibromo-
and iodoquinazolinone derivatives were very low as they
did not cause any mortality of rats in excess of 800 mg/kg
body weight.
Preparation of High Cholesterol Diet
The high cholesterol diet was prepared as previously
described [16]. 1% cholesterol (w/w) and 0.2% sodium
cholate (w/w) were well mixed with the finely-ground
commercial diet.
Induction of Diabetes Mellitus
Induction of diabetes mellitus in rats was carried out by a
single i.p. injection of freshly prepared alloxan monohy-
drate (Sigma, USA) solution at a concentration of 120 mg/
kg body weight after a fast of 12 h. [17]. After 3 days of
diabetes mellitus induction rats were put on the high cho-
lesterol diet for 4 weeks.
Study Design
Rats were allocated into 4 main reference groups (I-IV) as
follows: Group I. Normal Controls (NC) comprised 8
normal rats fed a normal diet and left intact without any
treatment, Group II. Vehicle Controls consisted of 8 nor-
mal rats fed a normal diet and received daily an oral dose
of 0.5 ml 10% polyethylene glycol, Group III. Hypercho-
lesterolemia, which was subdivided into 5 subgroups (8
rats each): (a) Hypercholesterolemia Controls, in which
rats fed a high cholesterol diet and left without any treat-
ment and (b, c, d, e) subgroups, which consisted of hyper-
cholesterolemic rats treated daily with a single oral dose of
bezafibrate, 4 (3H) quinazolinone, 6, 8-dibromo or 6-
iodo-2-methyl-4 (3H) quinazolinone, respectively, and
Group IV. Combined Hypercholesterolemia (C), which
was also subdivided into 5 subgroups (8 rats each): (a)
Diabetes- Hypercholesterolemia controls, in whichLipids in Health and Disease 2005, 4:22 http://www.lipidworld.com/content/4/1/22
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diabetic rats fed a high cholesterol diet and left without
any treatment and (b, c, d, e) subgroups, in which diabetic
rats fed a high cholesterol diet and treated daily with a sin-
gle oral dose of bezafibrate, 4 (3H) quinazolinone, 6, 8-
dibromo or 6-iodo-2-methyl-4 (3H) quinazolinone,
respectively.
Treatment with the different compounds started on the
same day of feeding high cholesterol diet and lasted for 4
weeks. Body weight of the animals in all groups was
recorded weekly until the end of the experiment.
Blood Collection and Tissue Sampling
Blood samples were taken from the retro-orbital venous
plexus under light ether anesthesia using a glass capillary
tube after a fast of 12 h. and immediately centrifuged.
Serum samples were aliquoted and stored at -20°C until
lipid profile analysis, except for fasting glucose, LDL and
HDL levels, which were determined on the same day with-
out delay. Liver was excised, rinsed from blood in isotonic
sterile saline, blotted dry and weighed. A weighed portion
of fresh liver tissue was dropped into a test tube contain-
ing concentrated sulphuric acid for total lipid determina-
tion. The remainder of liver tissue was stored in
physiological saline at -20°C until biochemical analysis.
Biochemical Assays
Fasting serum glucose level was determined by an enzy-
matic colorimetric method [18] using a commercial assay
kit (Diamond Diagnostics, Egypt). Serum and hepatic
total cholesterol and cholesterol ester levels were meas-
ured according to Zlatkis et al. [19]. Serum triacylglycerol
level was assayed by the method of Jacobs and Van Den-
mark [20] (Diamond Diagnostics, Egypt). Serum and
hepatic total lipid levels were determined as described by
Knight et al. [21]. Serum HDL-C [22] and LDL-C levels
[23] were also assessed (Diamond Diagnostics, Egypt and
Quimica Clinica Aplicada, Spain, respectively). Serum
VLDL-C level and the atherogenic index were determined
by calculation [24,25]. Liver and kidney function tests
Changes in the percentage of body weight gain in hypercho- lesterolemic rats treated with the different modalities  throughout the experimental period Figure 1
Changes in the percentage of body weight gain in hypercho-
lesterolemic rats treated with the different modalities 
throughout the experimental period. *denotes statistical sig-
nificance (p < 0.05) at the 4th week point compared to nor-
mal controls.
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Changes in the percentage of body weight gain in diabetic- hypercholesterolemic rats treated with the different modali- ties throughout the experimental period Figure 2
Changes in the percentage of body weight gain in diabetic-
hypercholesterolemic rats treated with the different modali-
ties throughout the experimental period. *denotes statistical 
significance (p < 0.05) at the 4th week point compared to 
normal controls.
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(serum albumin, urea, creatinine, alanine and aspartate
aminotransferases activity) were determined using com-
mercial assay kits (Diamond Diagnostics, Egypt). The con-
centrations of triacylglycerol and malondialdehyde were
also estimated in the whole liver homogenate (5%)
[26,27].
Statistical Analysis
Data were expressed as means ± SD and the least signifi-
cant difference (LSD) test for multiple comparisons
between the different treated subgroups and along with
their respective controls was applied [28].
Results
Fig. 1 shows a gradual increase in the percentage of total
body weight gain in hypercholesterolemic rats treated
with bezafibrate, quinazolinone and its halogenated
derivatives throughout the experimental period. Non sig-
nificant changes were recorded in the percentage of body
weight gain in the treated subgroups at the 4th week point,
except for the bezafibrate-treated subgroup, which
showed a significant decrease compared to normal
controls.
Fig. 2 demonstrates irregular changes in the percentage of
body weight gain in diabetic-hypercholesterolemic rats
treated with bezafibrate, quinazolinone and its halogen-
ated derivatives culminated in a highly significant reduc-
tion at the end of the experiment, which reached 79.32,
74.92, 85.32 and 59.48% (P < 0.01), respectively, com-
pared to normal controls.
Table 1 illustrates non significant differences in relative
liver weights in both non diabetic and diabetic-hypercho-
lesterolemic groups treated with the different compounds.
Table 2 shows that treatment of hypercholesterolemic rats
with bezafibrate, quinazolinone, dibromo- and iodo-
derivatives caused a significant reduction in fasting serum
glucose level, which reached 11.63, 29.78, 22.47 and
29.40%, respectively, compared to the control group.
Multiple comparison analysis showed that quinazolinone
and its halogenated derivatives produced a more pro-
nounced antihyperglycemic effect than bezafibrate. Bezaf-
ibrate and the three quinazolinone compounds gave rise
to a comparable decrease of 18.12, 27.73, 31.66 and
32.31%, respectively, in serum total lipids concentration.
A parallel reduction in serum triacylglycerol level was
noticed in bezafibrate (26.65%), dibromo- (16.83%) and
iodoquinazolinone (15.74%) subgroups, compared to
the control group. Treatment with bezafibrate, quina-
zolinone and its dibromo-derivative caused a comparable
reduction in serum total cholesterol and cholesterol ester
levels, which reached 28.78 & 37.7, 39.93 & 47.77 and
41.41 & 46.85%, respectively. Iodoquinazolinone
showed a more notable decrease of 43.83 and 50.78%,
Table 1: Effects of bezafibrate, quinazolinone and its halogenated derivatives on relative liver weights of rats with single and combined 
hypercholesterolemia compared to normal controls.
Single Hypercholesterolemia Combined Hypercholesterolemia
Groups Liver wt./b.wt. Groups Liver wt./b.wt.
N.C N.C
Mean ± SD 0.031 ± 0.005 Mean ± SD 0.031 ± 0.005
Range (0.024–0.039) Range (0.024–0.039)
HCD+B C+B
Mean ± SD 0.030 ± 0.003 Mean ± SD 0.037 ± 0.005
Range (0.025–0.032) Range (0.032–0.045)
Change% -11.76 Change% 5.71
HCD+Q C+Q
Mean ± SD 0.033 ± 0.003 Mean ± SD 0.030 ± 0.002
Range (0.029–0.037) Range (0.028–0.033)
Change% -2.94 Change% -14.29
HCD+BrQ C+BrQ
Mean ± SD 0.031 ± 0.003 Mean ± SD 0.029 ± 0.003
Range (0.028–0.035) Range (0.025–0.036)
Change% -8.82 Change% -17.14
HCD+IQ C+IQ
Mean ± SD 0.030 ± 0.002 Mean ± SD 0.030 ± 0.001
Range (0.027–0.032) Range (0.027–0.031)
Change% -11.76 Change% -14.29Lipids in Health and Disease 2005, 4:22 http://www.lipidworld.com/content/4/1/22
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respectively. Serum free cholesterol and HDL-C levels
were insignificantly changed in all treatment subgroups.
In contrast, significantly parallel reductions in serum LDL-
C level and atherogenic index were recorded in all treated
subgroups, and reached 38.56 & 41.29, 55.03 & 56.73,
55.65 & 49.91 and 54.44 & 37.70% in bezafibrate, quina-
zolinone, dibromo- and iodoquinazolinone, respectively.
Serum VLDL-C level was significantly reduced in bezafi-
brate (26.63%), dibromo- (16.83%) and iodoquina-
zolinone (15.72%) subgroups, compared to controls.
Multiple comparison analysis showed non significant
changes in serum VLDL-C level among the different treat-
ment subgroups.
Table 3 illustrates that treatment of diabetic-hypercholes-
terolemic rats with bezafibrate caused significant reduc-
tions in fasting serum glucose and total lipid levels (17.36
and 23.84%, respectively), while more pronounced
reductions were recorded after treatment with quina-
zolinone (67.48 & 48.32%), dibromo- (66.09 & 49.76%)
and iodo- derivatives (67.39 & 47.52%), compared to the
control group. Significant decreases were recorded in
Table 2: Statistical significance of fasting serum glucose level and lipid profile in hypercholesterolemic rats treated with bezafibrate, 
quinazolinone and halogenated derivatives, compared to control group.
Parameters HCD HCD+B HCD+Q HCD+BrQ HCD+IQ
Glucose(mg/dl)
Mean ± SD 123.57 ± 11.99a 109.20 ± 14.31b 86.77 ± 9.87c 95.80 ± 8.28c 87.24 ± 5.32c
Range (105.11–135.02) (82.69–125.22) (77.45–106.22) (86.36–111.10) (77.54–93.81)
Change% - -11.63 -29.78 -22.47 -29.40
Total lipids(g/L)
Mean ± SD 4.58 ± 0.67a 3.75 ± 0.68b 3.31 ± 0.95b 3.13 ± 0.43b 3.10 ± 0.78b
Range (3.62–5.67) (2.82–4.79) (2.02–4.54) (2.40–3.90) (2.17–4.72)
Change% - -18.12 -27.73 -31.66 -32.31
T.G.(mg/dl)
Mean ± SD 94.46 ± 14.23a 69.29 ± 11.04b 87.05 ± 9.18ac 78.56 ± 12.79bc 79.59 ± 15.94bc
Range (73.33–108.89) (54.40–86.65) (75.56–102.22) (66.67–98.50) (52.44–100.89)
Change% - -26.65 -7.84 -16.83 -15.74
T.Cholesterol(mg/dl)
Mean ± SD 159.06 ± 26.04a 113.28 ± 17.52b 95.55 ± 18.11bc 93.19 ± 14.29bc 89.35 ± 22.37c
Range (119.35–87.50) (95.93–139.06) (75.63–121.41) (65.63–104.69) (70.31–123.44)
Change% - -28.78 -39.93 -41.41 -43.83
F.Cholesterol(mg/dl)
Mean ± SD 36.66 ± 7.14a 37.88 ± 8.94a 32.12 ± 8.15a 29.45 ± 4.11a 30.14 ± 6.39a
Range (25.76–45.20) (29.59–52.36) (21.14–46.18) (22.11–33.82) (25.04–40.33)
Change% - 3.33 -12.38 -19.67 -17.79
E.Cholesterol(mg/dl)
Mean ± SD 122.40 ± 19.10a 76.25 ± 8.89b 63.93 ± 10.02bc 65.05 ± 7.96bc 60.25 ± 15.29c
Range (91.85–142.30) (66.01–89.04) (50.54–76.01) (54.00–74.33) (43.32–83.11)
Change% - -37.7 -47.77 -46.85 -50.78
HDL-C (mg/dl)
Mean ± SD 24.27 ± 3.23 a 27.73 ± 5.48a 28.33 ± 6.15a 25.68 ± 6.34a 21.14 ± 8.93a
Range (19.75–28.80) (18.30–35.15) (20.36–36.00) (18.92–33.32) (14.44–37.84)
Change% - 14.26 16.73 5.81 -12.90
LDL-C (mg/dl)
Mean ± SD 116.09 ± 26.74a 71.32 ± 17.78 b 52.20 ± 15.23b 51.49 ± 10.43 b 52.89 ± 19.31b
Range (74.82–141.75) (49.96–89.66) (32.83–76.84) (29.54–62.17) (26.84–79.28)
Change% - -38.56 -55.03 -55.65 -54.44
VLDL-C (mg/dl)
Mean ± SD 18.89 ± 2.85a 13.86 ± 2.21b 17.41 ± 1.84ac 15.71 ± 2.56bc 15.92 ± 3.19bc
Range (14.67–21.78) (10.88–17.33) (15.11–20.44) (13.33–19.70) (10.49–20.18)
Change% - -26.63 -7.83 -16.83 -15.72
A.I.
Mean ± SD 5.57 ± 0.87a 3.27 ± 1.30b 2.41 ± 0.42b 2.79 ± 1.02b 3.47 ± 0.91b
Range (4.22–7.21) (1.80–6.11) (1.94–3.14) (1.67–4.52) (2.26–4.70)
Change% - -41.29 -56.73 -49.91 -37.70
For each parameter similar characters denote insignificance between groups. The mean difference is significant at p < 0.05.Lipids in Health and Disease 2005, 4:22 http://www.lipidworld.com/content/4/1/22
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serum levels of total cholesterol and cholesterol ester lev-
els after treatment with quinazolinone (43.66 & 62.33%),
dibromo- (49.86 & 55.34%) and iodo-derivative (49.12 &
56.74%, respectively), whereas bezafibrate caused a less
notable decrease of serum cholesterol ester level (19.93%)
and did not affect total cholesterol level. None of the fore-
going treatments significantly affected serum triacylglyc-
erol, HDL-C and VLDL-C levels. Treatment of diabetic-
hypercholesterolemic rats with quinazolinone, dibromo-
and iodo- derivatives produced significant decreases in
serum LDL-C level (71.74, 65.69 and 60.74%, respec-
tively) and atherogenic index (50.24, 69.54 and 51.99%).
Bezafibrate treatment caused a slight but significant
reduction in the atherogenic index (28.39%), while serum
LDL-C level remains unchanged.
Table 4 demonstrates that treatment of hypercholestero-
lemic rats with bezafibrate, quinazolinone, dibromo- and
iodo- derivatives caused a significant parallel reduction in
hepatic total lipids concentration (20.11, 30.80, 25.01
Table 3: Statistical significance of serum fasting glucose level and lipid profile in diabetic-hypercholesterolemic rats treated with 
bezafibrate, quinazolinone and halogenated derivatives.
Parameters C C+B C+Q C+BrQ C+IQ
Glucose(mg/dl)
Mean ± SD 210.34 ± 16.56a 173.82 ± 26.86b 68.40 ± 5.22c 71.32 ± 8.42c 68.60 ± 5.66c
Range (189.24–230.00) (140.00–218.00) (61.65–79.47) (60.55–85.00) (60.76–75.36)
Change% - -17.36 -67.48 -66.09 -67.39
Total lipids(g/L)
Mean ± SD 6.25 ± 2.29a 4.76 ± 0.85b 3.23 ± 1.08c 3.14 ± 0.63c 3.28 ± 0.77c
Range (2.32–9.51) (3.76–5.96) (2.02–4.64) (2.02–4.15) (2.20–4.34)
Change% - -23.84 -48.32 -49.76 -47.52
T.G(mg/dl)
Mean ± SD 110.42 ± 18.75a 91.91 ± 15.64a 109.51 ± 31.98a 99.00 ± 15.06a 100.64 ± 10.33a
Range (88.14–133.33) (70.00–111.11) (66.67–165.00) (73.33–121.14) (86.67–117.11)
Change% - -16.76 -0.82 -10.34 -9.72
T.Cholesterol(mg/dl)
Mean ± SD 176.28 ± 42.14a 152.76 ± 36.36a 99.31 ± 22.80b 88.38 ± 26.64b 89.69 ± 10.02b
Range (127.34–224.38) (106.25–199.22) (74.22–126.56) (65.63–134.38) (73.44–104.22)
Change% - -13.34 -43.66 -49.86 -49.12
F.Cholesterol(mg/dl)
Mean ± SD 39.19 ± 11.02ab 44.37 ± 9.44a 30.31 ± 6.98b 30.03 ± 6.73b 31.06 ± 5.43b
Range (25.62–51.89) (28.62–53.98) (20.16–40.98) (23.09–41.30) (26.02–41.63)
Change% - 13.22 -22.66 -23.37 -20.75
E.Cholesterol(mg/dl)
Mean ± SD 135.37 ± 31.41a 108.39 ± 31.2b 69.00 ± 18.80c 60.46 ± 16.43c 58.56 ± 6.96c
Range (101.72–170.75) (77.63–145.24) (49.18–96.97) (48.40–88.08) (47.42–65.67)
Change% - -19.93 -62.33 -55.34 -56.74
HDL-C(mg/dl)
Mean ± SD 24.76 ± 3.62a 25.88 ± 2.74a 24.87 ± 4.71a 26.71 ± 2.58a 22.50 ± 1.77a
Range (18.00–27.94) (21.13–29.60) (19.83–31.52) (22.40–30.33) (19.80–24.32)
Change% - 4.52 0.44 7.88 -9.13
LDL-C(mg/dl)
Mean ± SD 115.29 ± 34.06a 84.56 ± 43.44a 32.58 ± 18.85b 39.56 ± 26.65b 45.26 ± 10.16b
Range (79.73–168.69) (44.05–137.56) (19.51–64.94) (16.24–82.42) (34.31–63.03)
Change% - -26.65 -71.74 -65.69 -60.74
VLDL-C(mg/dl)
Mean ± SD 22.08 ± 3.75a 18.38 ± 3.13a 22.52 ± 6.28a 19.80 ± 3.01a 20.13 ± 2.07a
Range (17.63–26.67) (14.00–22.22) (13.33–33.00) (14.67–24.23) (17.33–23.42)
Change% - -1.67 1.99 -10.33 -8.83
A.I.
Mean ± SD 6.27 ± 2.06a 4.49 ± 1.53b 3.12 ± 1.20b 1.91 ± 1.27b 3.01 ± 0.57b
Range (3.56–9.80) (2.59–6.91) (1.65–4.82) (0.99–4.33) (2.21–3.79)
Change% - -28.39 -50.24 -69.54 -51.99
For each parameter similar characters denote insignificance between groups.
The mean difference is significant at p < 0.05.Lipids in Health and Disease 2005, 4:22 http://www.lipidworld.com/content/4/1/22
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and 25.21%, respectively) associated with a significant
comparable elevation in hepatic malondialdehyde con-
centration (74.95, 63.11, 49.84 and 60.81%), compared
to the control group. Hepatic triacylglycerol concentration
was significantly decreased in bezafibrate (43.03%),
dibromo- (25.59%) and iodoquinazolinone (23.70%)
subgroups, while it remains unchanged in quinazolinone
subgroup, compared to the control group. A significant
elevation in hepatic free cholesterol and, in contrast a sig-
nificant decrease of hepatic cholesterol ester concentra-
tions were recorded in quinazolinone (120.34 & 50.67%,
respectively), dibromo-(66.21 & 32.09%) and iodoquina-
zolinone (63.28 & 31.06%) subgroups. The LSD test
revealed that halogenated quinazolinones exerted a more
pronounced effect on cholesterol fractions than quina-
zolinone. Bezafibrate produced no significant effect on
hepatic cholesterol fractions. Also, hepatic total choles-
terol concentration was not significantly changed in all
treatment subgroups.
Table 5 shows that hepatic total lipids, triacylglycerol,
total cholesterol and malondialdehyde concentrations
were not significantly changed in diabetic-hypercholeste-
rolemic rats treated with quinazolinone and its halogen-
ated derivatives. A significant parallel elevation in hepatic
free cholesterol and, in contrast a significant parallel
decrease of hepatic cholesterol ester concentrations were
recorded in quinazolinone (65.53 & 32.62%, respec-
tively), dibromo-(68.94 & 30.48%) and iodoquina-
zolinone subgroups (67.44 & 25.59%). Bezafibrate
treatment had no significant effect on all of the foregoing
parameters.
Discussion
Although the literature implies a few evidence about the
antihyperlipidemic activity of some quinazolinone deriv-
atives, yet intensive research in quinazolinone chemistry
is still in progress as indicated by the continuous flow of
newly appearing derivatives. In the present study, we have
demonstrated the effects of quinazolinone and two halo-
genated derivatives on the lipid profile in single and com-
bined hypercholesterolemia in rats. Alloxan was used to
induce diabetes mellitus in rats and, surprisingly treat-
ment of single and combined hypercholesterolemia
groups with quinazolinone compounds for 4 weeks sig-
nificantly decreased the fasting serum glucose level, com-
pared to bezafibrate and their respective control groups
(Tables 2 &3). Although the antihyperglycemic activity of
Table 4: Statistical significance of hepatic lipid profile and malondialdehyde concentration in hypercholesterolemic rats treated with 
bezafibrate, quinazolinone and halogenated derivatives, compared to control group
Parameters HCD HCD+B HCD+Q HCD+BrQ HCD+IQ
Total lipids
Mean ± SD 75.30 ± 7.86a 60.16 ± 4.18b 52.11 ± 13.07b 56.47 ± 9.50b 56.32 ± 12.94b
Range (68.24–88.24) (54.90–66.27) (36.86–74.90) (41.57–68.24) (41.57–76.08)
Change% - -20.11 -30.80 -25.01 -25.21
Triacylglycerol
Mean ± SD 10.55 ± 2.66a 6.01 ± 1.39b 9.83 ± 2.17a 7.85 ± 2.75b 8.05 ± 1.35b
Range (7.09–14.91) (4.09–7.83) (7.30–13.91) (4.39–11.74) (6.65–10.50)
Change% - -43.03 -6.82 -25.59 -23.70
Total cholesterol
Mean ± SD 25.18 ± 2.77ab 25.64 ± 1.48a 22.71 ± 2.13b 22.80 ± 2.01b 22.83 ± 2.13b
Range (20.58–28.46) (23.98–28.32) (19.11–25.85) (20.00–25.39) (19.12–25.61)
Change% - 1.83 -9.81 -9.45 -9.33
Free cholesterol
Mean ± SD 5.80 ± 1.70a 5.23 ± 1.32a 12.78 ± 2.46b 9.64 ± 1.30c 9.47 ± 1.50c
Range (3.37–8.13) (3.85–6.83) (9.52–17.33) (7.68–11.45) (7.22–11.51)
Change% - -9.83 120.34 66.21 63.28
Ester cholesterol
Mean ± SD 19.38 ± 1.67a 20.42 ± 1.00a 9.56 ± 1.56b 13.16 ± 1.30c 13.36 ± 1.20c
Range (16.99–21.76) (19.35–22.47) (7.57–11.43) (11.11–14.51) (11.67–15.56)
Change% - 5.37 -50.67 -32.09 -31.06
MDA(nmol/g)
Mean ± SD 131.31 ± 15.10a 229.73 ± 4.76b 214.18 ± 23.85b 196.75 ± 26.44b 211.16 ± 14.54b
Range (113.33–155.42) (223.53–238.43) (172.42–246.01) (161.57–229.28) (188.37–230.33)
Change% - 74.95 63.11 49.84 60.81
All parameters are expressed in mg/g tissue unless otherwise stated.
For each parameter similar characters denote insignificance between groups.
The mean difference is significant at p < 0.05.Lipids in Health and Disease 2005, 4:22 http://www.lipidworld.com/content/4/1/22
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these compounds was not intentionally studied, this
effect could be attributed to being cyclic amidine
compounds. Metformin, a well known hypoglycemic
drug, which acts as an inhibitor of hepatic glucose produc-
tion, possesses guanidine and amidine functionalities in
its molecular structure. Another class of compounds,
triarylimidazoles, which has also an amidine moiety in a
cyclic structure, displayed a significant glucagon antago-
nistic property [29]. The antihyperglycemic activity of the
quinazolinone compounds is worth to be adequately
investigated.
The quinazolinone compounds, being water insoluble,
were dissolved in 10% polyethylene glycol as a solvent
and thus a vehicle control group was established to evalu-
ate its effect on all studied serum and liver tissue parame-
ters. Statistical analysis showed that polyethylene glycol
had no significant effect on the body weight of animals, as
well as all serum and liver tissue parameters (data not
shown). Accordingly, statistical significance was referred
to the normal control or the reference groups.
In order to assess the toxic side effects of the administered
dose levels of quinazolinone compounds, the change per-
cent of body weight gain at each week point with respect
to the initial body weight was recorded. In comparison to
normal controls at the 4th week point, hypercholestero-
lemic rats treated with quinazolinone compounds exhib-
ited non significant changes in the percentage of body
weight gain, except for bezafibrate subgroup, which
showed a significant reduction (P < 0.01) (Fig. 1). Dia-
betic-hypercholesterolemic rats manifested a significant
decrease in the percentage of body weight gain (P < 0.01)
in the different treatment modalities (Fig. 2). This clearly
indicates that quinazolinone compounds had no signifi-
cant effect on body weight, and that the reduction in the
body weight gain of diabetic- hypercholesterolemic ani-
mals was mainly due to diabetes mellitus. Sellei et al. [30]
reported that treatment with a therapeutic dose of any
compound on the body weight loss must not exceed 10%.
Also, Bissery et al. [31] stated that a drug dosage that pro-
duces a loss in body weight of 20% is considered as exces-
sively toxic. Feron et al. [32] documented that in
subchronic toxicity experiments, the weights of the major
organs of the body may serve as a useful index of toxicity.
However, decreased absolute weights in treated animals
may be merely a reflection of lower body weight, thus cal-
culation of organ weight to whole body weight ratio justi-
Table 5: Statistical significance of hepatic lipid profile and malondialdehyde concentration in diabetic-hypercholesterolemic rats 
treated with bezafibrate, quinazolinone and halogenated derivatives
Parameters C C+B C+Q C+BrQ C+IQ
Total lipids
Mean ± SD 74.76 ± 7.34a 65.00 ± 7.37a 71.37 ± 6.01a 65.93 ± 11.54a 66.12 ± 9.47a
Range (65.88–84.71) (54.90–76.47) (62.16–77.65) (45.49–81.57) (48.92–78.43)
Change% - -13.06 -4.53 -11.81 -11.56
Triacylglycerol
Mean ± SD 12.10 ± 3.37a 9.90 ± 1.08a 11.90 ± 4.38a 12.03 ± 5.07a 11.80 ± 4.82a
Range (8.87–17.30) (8.38–11.30) (7.48–16.61) (6.09–18.78) (6.23–17.30)
Change% - -18.18 -1.65 -0.58 -2.48
Total cholesterol
Mean ± SD 26.53 ± 4.93a 26.58 ± 3.37a 23.87 ± 3.58a 25.62 ± 2.94a 26.57 ± 2.88a
Range (20.05–34.15) (21.14–31.71) (18.79–28.86) (23.58–32.52) (22.08–30.08)
Change% - 0.19 -10.03 -3.43 0.15
Free cholesterol
Mean ± SD 7.34 ± 2.45a 7.49 ± 1.93a 12.15 ± 2.42b 12.40 ± 3.17b 12.29 ± 2.59b
Range (4.04–10.41) (5.69–11.32) (8.29–16.03) (8.85–18.31) (8.98–14.80)
Change% - 2.04 65.53 68.94 67.44
Cholesterol ester
Mean ± SD 19.19 ± 2.61a 19.19 ± 1.95a 12.93 ± 2.78b 13.34 ± 2.77b 14.28 ± 3.82b
Range (15.31–23.74) (16.26–21.93) (9.25–16.69) (10.36–18.21) (9.57–19.02)
Change% - 0 -32.62 -30.48 -25.59
MDA(nmol/g)
Mean ± SD 235.18 ± 16.32a 238.29 ± 18.23a 250.98 ± 12.06a 250.23 ± 13.03a 244.19 ± 13.45a
Range (210.72–256.47) (218.99–269.02) (234.51–267.97) (237.65–276.24) (221.17–257.91)
Change% - 1.32 6.72 6.40 3.83
All parameters are expressed in mg/g tissue unless otherwise stated.
For each parameter similar characters denote insignificance between groups.
The mean difference is significant at p < 0.05.Lipids in Health and Disease 2005, 4:22 http://www.lipidworld.com/content/4/1/22
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fies the usefulness of the data obtained. In the present
study, relative liver weights were recorded, as liver is the
main site of drug activation and detoxification. Non sig-
nificant differences in relative liver weights were observed
in single and combined hypercholesterolemia subgroups
(Table 1). Also, non significant alterations were recorded
in serum levels of aminotransferases activity (ALT&AST)
and albumin, as well as urea and creatinine concentra-
tions, compared to normal controls (data not shown),
which indicates the safety of the quinazolinone com-
pounds at the adopted dose levels.
A comparable reduction in serum and hepatic triacylglyc-
erol levels is reported in hypercholesterolemic rats treated
with bezafibrate, dibromo- and iodoquinazolinone sub-
groups, compared to their reference groups (Tables 2 &4),
which demonstrates that halogens substitution in the
quinazolinone nucleus confered a triacylglycerol-lower-
ing effect to the parent quinazolinone compound. How-
ever, this observation was not noticed in combined
hypercholesterolemia (Tables 3 &5) and may be inter-
preted as simply due to increased fat mobilization as a
result of insulin deficiency manifested by the significant
reduction in the body weight of the animals at decapita-
tion (Fig. 2).
The cholesterol-lowering effect of quinazolinone and its
dibromo-and iodo-derivatives is represented by compara-
ble reductions in serum total cholesterol and cholesterol
ester levels in single and combined hypercholesterolemia
(Tables 2 &3), which might be due to inhibition of dietary
cholesterol absorption and/or its esterification. Since two
enzymes are involved in these two processes; pancreatic
cholesterol esterase [33] and intestinal acyl CoA-choles-
terol acyl transferase enzyme (ACAT) [34], thus it could be
suggested that quinazolinones inhibit one or both
enzymes activity. The assumption that quinazolinones
inhibit ACAT activity is confirmed by the significant
decrease of hepatic cholesterol ester concentration and, in
contrast the significant increase of hepatic free cholesterol
concentration (Tables 4 &5). The remarkable elevation in
hepatic MDA concentration in single hypercholestero-
lemia after treatment with quinazolinones, compared to
their reference group (Table 4) may be explained due to
increased fatty acids pool and consequently its peroxida-
tion as a result of ACAT inhibition by quinazolinone com-
pounds (as previously mentioned). Another suggestion
for the cholesterol-lowering effect of the quinazolinones
is the interaction between quinazolinones and choles-
terol, which inhibits its entry into the enterocytes, thus
not providing the required cholesterol pool for
esterification.
Parallel results affirmed [16] a significant reduction in
serum total cholesterol and unchanged hepatic total cho-
lesterol concentrations in high cholesterol-fed rats treated
with 1 mg/Kg quinazoline derivative (4-amino-2-(4-
(bicycle (2, 2, 2) oct-2-ene-5-carbonyl)-1-piperazinyl)-6,
7-dimethoxy-quinazoline). The authors ascribed their
findings due to direct inhibition of cholesterol absorption
or due to increased biliary excretion of sterol and/or bile
acids and the block of cholesterol movement from the
liver to the blood.
Also, it is turned out that halogens substitution of quina-
zolinone has a negative effect on inhibition of hepatic
cholesterol esterification displayed by the less pro-
nounced reduction in hepatic free cholesterol and, in con-
trast the more notable elevation in hepatic cholesterol
ester concentrations, compared to quinazolinone (Table
4). Surprisingly, this phenomenon was not observed in
case of combined hypercholesterolemia (Table 5). In
comparison to bezafibrate, iodoquinazolinone was found
to produce a significant more pronounced reduction in
serum total cholesterol and cholesterol ester levels. In case
of combined hypercholesterolemia, treatment with
quinazolinone and its dibromo- and iodo-derivatives pro-
duced a significantly favorable effect on serum and
hepatic cholesterol profiles than bezafibrate (Tables 3
&5).
In regard to serum lipoproteins profile, the 3 quina-
zolinones reduced more or less equally serum LDL-C
level, whereas serum VLDL-C level was highly reduced by
dibromo- and iodoquinazolinone, compared to their ref-
erence group. The quinazolinone compounds did not
affect significantly serum HDL-C level (Table 2). Taken
together, these findings furtherly confirm the inhibitory
effect of quinazolinones on cholesterol esterification, as it
is well known that LDL particles have a high affinity to
bind to cholesterol ester, while it is free cholesterol in case
of HDL [35], and that halogens substitution of the quina-
zolinone increases its triacylglycerol-lowering activity.
Consistent with our results, Seki et al. [16] referred the
decrease of serum total cholesterol level in quinazoline
derivative-treated rats to reduction in serum VLDL-C and
LDL-C rather than HDL-C levels.
In combined hypercholesterolemia subgroups serum
HDL-C and VLDL-C levels were not significantly affected
by any of the treatments, whereas serum LDL-C level was
significantly decreased by quinazolinones treatment,
compared to either bezafibrate or their reference group
(Table 3). It is interesting to remark that the more notable
reduction in serum LDL-C level in combined than single
hypercholesterolemia subgroups might be a sequela of
enhanced lipid peroxidation in the former, which con-
verted LDL to modified LDL, including glycosylated, oxi-
dized and small dense LDL particles [36]. Increased liver
malondialdehyde (MDA) concentration in the combinedLipids in Health and Disease 2005, 4:22 http://www.lipidworld.com/content/4/1/22
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hypercholesterolemia subgroups confirms this explana-
tion (Tables 4 &5). However, the non significant changes
in hepatic MDA concentration in the different diabetic-
hypercholesterolemic subgroups, compared to their refer-
ence group, may be due to enhanced lipolysis in diabetes
mellitus that exceeded the effects of quinazolinone com-
pounds against LDL peroxidation, which was displayed in
non diabetic animals.
Our results are in line with those of Hsun et al. [37], who
stated that quinazoline derivatives reduce significantly the
level of serum LDL-C with respect to the cholesterol
reference group. Previous studies documented that serum
LDL-C reduction is due to inhibition of hepatic apoB
secretion, which is the main apolipoprotein in LDL parti-
cles that is recognized by the LDL receptor, and that cho-
lesterol ester availability may be important in regulating
apo B secretion. Carr et al. [38,39] affirmed that when
ACAT is highly inhibited in African green monkey, both
apo B and cholesterol ester secretion are reduced, but
when ACAT is moderately inhibited cholesterol ester
secretion may be reduced without affecting apo B
secretion.
Data presented in Tables (2 &3) demonstrate a significant
reduction in the atherogenic index (AI) in the quina-
zolinones-treated subgroups of non diabetic and diabetic
hypercholesterolemic rats, compared to their respective
reference groups. Non significant differences in the ather-
ogenic index were noticed between the quinazolinones
and the bezafibrate. The reduced atherogenic index in
both treatments was mainly due to the decrease in serum
total cholesterol level rather than elevation in serum HDL-
C level.
Conclusion
1-Subchronic treatments of non diabetic and diabetic-
hypercholesterolemic rats with 4(3H)-quinazolinone and
its 6, 8-dibromo and 6-iododerivatives (4 weeks) have no
significant toxic side effects at the adopted sublethal dose
levels (2 mg/Kg).
2-Quinazolinone and its halogenated derivatives possess
potential antihyperlipidemic activity in single and com-
bined hypercholesterolemia demonstrated by the dra-
matic reduction in serum total cholesterol and cholesterol
ester levels, and most importantly LDL-C, which is a
major risk factor for coronary and cerebral vascular
atherosclerosis. The mode of action of quinazolinone
compounds is possibly through inhibition of dietary cho-
lesterol absorption and intestinal ACAT activity.
3-Halogen derivatization of quinazolinone confers a tria-
cylglycerol-lowering activity to the parent compound in
case of single hypercholesterolemia only.
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